glp-1 conference Consumers Using GLP-1s for Weight Loss Drive Lasting Changes in Retail Obesity Medicine 2025 - Conference

Compounded medications are not reviewed or approved by the FDA for safety or effectiveness

Notably, the absence of LAT1 impedes the differentiation pathways of Th1, Th2, and Th17 cells, acting independently of T cell receptor signals but via the PI3K/Akt/mTOR pathway

27 These conditions, including the antibodies used and the recombinant human Trx1 standards utilized, impacted accuracy of measurement and contributed to huge differences in Trx1 levels between studies, making between-study comparisons very difficult

Given the translational uncertainty, the ROI for an 85 mg/day intranasal protocol is currently speculative

Dosage should be individualized to obtain an adequate response with the lowest effective dose